Hyperlipidemia is associated with altered levels of insulin-like growth factor-I

Title:

Hyperlipidemia is associated with altered levels of insulin-like growth factor-I

Creator:

Jan Malík, Tomáš Štulc, Dan Wichterle, Vojtěch Melenovský, Eva Chytilová, Zdeňka Lacinová, Jan Marek, and Richard Češka

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:9c39e696-62af-4701-a189-8147a8cb0e38
uuid:9c39e696-62af-4701-a189-8147a8cb0e38
issn:0862-8408

Subject:

Biochemie. Molekulární biologie. Biofyzika, fyziologie, ateroskleróza, růstové faktory, inzulinová rezistence, syndrom inzulinové rezistence, human physiology, growth factors, insulin resistance, cholesterol, insulin resistance syndrome, 2, and 577

Type:

article, články, model:article, and TEXT

Format:

print, bez média, and svazek

Description:

Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expected IGF-I and IGFBP-3 alterations in subjects with moderate/severe hyperlipidemia but without any clinical manifestation of atherosclerosis. Total IGF-I and IGFBP-3 were assessed in 56 patients with mixed hyperlipidemia (MHL; cholesterol>6.0 mmol/l, triglycerides>2.0 mmol/l), in 33 patients with isolated hypercholesterolemia (IHC; cholesterol>6.0 mmol/l, triglycerides<2.0 mmol/l), and in 29 healthy controls (cholesterol<6.0 mmol/l, triglycerides<2.0 mmol/l). The molar ratio of IGF-I/IGFBP-3 was used as a measure of free IGF-I. IHC subjects differed from controls by lower total IGF-I (164±60 vs. 209±73 ng/ml, p=0.01) and IGF-I/IGFBP-3 ratio (0.14±0.05 vs. 0.17±0.04, p=0.04). Compared to controls, MHL subjects had lower total IGF-I (153±54 ng/ml, p=0.0002) and IGFBP-3 (2.8±0.6 mg/ml, p<0.0001), but higher IGF-I/IGFBP-3 ratio (0.25±0.06, p<0.0001). Differences remained significant after the adjustment for clinical and biochemical covariates, except for triglycerides. Patients with both IHC and MHL have lower total IGF-I compared to controls. The mechanism is presumably different in IHC and MHL. Because of prominent reduction of IGFBP-3 in patients with MHL, they have reduced total IGF-I despite the actual elevation IGF-I/IGFBP-3 ratio as a surrogate of free IGF-I., J. Malík, T. Štulc, D. Wichterle, V. Melenovský, E. Chytilová, Z. Lacinová, J. Marek, R. Češka., and Obsahuje bibliografii a bibliografické odkazy

Language:

English

Rights:

http://creativecommons.org/licenses/by-nc-sa/4.0/
policy:public

Source:

Physiological research | 2008 Volume:57 | Number:6

Harvested from:

CDK

Metadata only:

false